Présentation orale

Modèle thérapeutique :

Garcia-Romeu, A., & Richards, W. A. (2018). Current perspectives on psychedelic therapy : Use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry, 30(4), 291‑316. https://doi.org/10.1080/09540261.2018.1486289

Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research : Guidelines for safety. Journal of Psychopharmacology, 22(6), 603‑620. https://doi.org/10.1177/0269881108093587

 

        Contexte législatif et opinion des professionnels au Canada :

Masse-Grenier, M., Chang, S.-L., Bélanger, A., Stephan, J.-F., Hébert, J., Deschamps, P., Plourde, L., Provost, F., Farzin, H., Fallu, J.-S., Dorval, M., & Group, P. R. (2024). What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study. Palliative & Supportive Care, 1‑11. https://doi.org/10.1017/S1478951524001494

Limites de la recherche actuelle :

E-Wen McCulloch, D., Liechti, M. E., Kuypers, K. PC., Nutt, D., Lundberg, J., Stenbæk, D. S., Goodwin, G. M., Gründer, G., Butlen-Ducuing, F., Haberkamp, M., Thirstrup, S., & Knudsen, G. M. (2024). Knowledge gaps in psychedelic medicalisation : Clinical studies and regulatory aspects. Neuroscience Applied, 3, 103938. https://doi.org/10.1016/j.nsa.2024.103938

 

Opinion des psychologues américains :

Davis, A. K., Agin-Liebes, Gabrielle, España, Megan, Pilecki ,Brian, & and Luoma, J. (2022). Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs, 54(4), 309‑318. https://doi.org/10.1080/02791072.2021.1971343

 

Importance de la participation du public :

Close, J. B., Bornemann, J., Piggin, M., Jayacodi, S., Luan, L. X., Carhart-Harris, R., & Spriggs, M. J. (2021). Co-design of Guidance for Patient and Public Involvement in Psychedelic Research. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.727496

 

Auteurs suggérant des thématiques de recherche en lien avec les aspects cliniques et pratiques :

Beaussant, Y., Sanders, J., Sager, Z., Tulsky, J. A., Braun, I. M., Blinderman, C. D., Bossis, A. P., & Byock, I. (2020). Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness : Expert Clinicians’ and Investigators’ Perspectives. Journal of Palliative Medicine, 23(10), 1323‑1334. https://doi.org/10.1089/jpm.2019.0603

E-Wen McCulloch, D., Liechti, M. E., Kuypers, K. PC., Nutt, D., Lundberg, J., Stenbæk, D. S., Goodwin, G. M., Gründer, G., Butlen-Ducuing, F., Haberkamp, M., Thirstrup, S., & Knudsen, G. M. (2024). Knowledge gaps in psychedelic medicalisation : Clinical studies and regulatory aspects. Neuroscience Applied, 3, 103938. https://doi.org/10.1016/j.nsa.2024.103938

Lehto, R. H., Miller, M., & Sender, J. (2022). The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer : A Critical Scoping Review of the Research. Journal of Holistic Nursing, 40(3), 265‑280. https://doi.org/10.1177/08980101211039086

Marseille, E., Bertozzi, S., & Kahn, J. G. (2022). The economics of psychedelic-assisted therapies : A research agenda. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.1025726

Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024). Unlocking the healing power of psilocybin : An overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1406888

Wall, M. B., Harding, R., Zafar, R., Rabiner, E. A., Nutt, D. J., & Erritzoe, D. (2023). Neuroimaging in psychedelic drug development : Past, present, and future. Molecular Psychiatry, 28(9), 3573‑3580. https://doi.org/10.1038/s41380-023-02271-0

Wheeler, S., & Dyer, N. (2020). A Systematic Review of Psychedelic-Assisted Psychotherapy for Mental Health : An Evaluation of the Current Wave of Research and Suggestions for the Future. Psychology of Consciousness: Theory, Research, and Practice, 7. https://doi.org/10.1037/cns0000237

Xi, D., Berger, A., Shurtleff, D., Zia, F. Z., & Belouin, S. (2023). National Institutes of Health psilocybin research speaker series : State of the science, regulatory and policy landscape, research gaps, and opportunities. Neuropharmacology, 230, 109467. https://doi.org/10.1016/j.neuropharm.2023.109467

 

Effets indésirables :

Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics : From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258‑272. https://doi.org/10.1177/02698811211069100

 

Mécanismes d’action :

Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. Journal of The Royal Society Interface, 11(101), 20140873. https://doi.org/10.1098/rsif.2014.0873

Neitzke-Spruill, L., Devenot, N., Sisti, D., Averill, L. A., & McGuire, A. L. (2024). Bio-Psycho-Spiritual Perspectives on Psychedelics : Clinical and Ethical Implications. Perspectives in Biology and Medicine, 67(1), 117‑142. https://doi.org/10.1353/pbm.2024.a919715